Work

33P: A multi-country time & motion (T&M) study of subcutaneous (SC) vs intravenous (IV) pembrolizumab (Pembro) plus chemotherapy (Chemo) in metastatic non-small cell lung cancer (mNSCLC)

Year: 2025

Type: article

Study design: Observational Study

Source: Journal of Thoracic Oncology

DOI: 10.1016/s1556-0864(25)00228-x

Authors: E. De Cock, S. Oskar, C. Lourdudoss, R. Eiras, C. Pietanza, A. Arunachalam, G.V. Alves, E. Felip

Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Vall d'Hebron Hospital Universitari

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4408979072

FWCI: 0.619

Cites:

Cited by: 1

Related to: 10